View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. NextGen Sciences
19 April 2010

NextGen Sciences to Develop and Validate Protein Biomarker Assays for Takeda Pharmaceuticals

NextGen Sciences, a leading provider of biomarker discovery, assay development, validation and testing services, and Takeda Pharmaceutical Company (Takeda), have entered into an agreement under which NextGen Sciences will develop validated protein biomarker assays to be used in Takeda’s preclinical and clinical studies to support their drive towards personalised medicine.

The biomarker assays will be designed to target specific protein isoforms found in liver and muscle in multiple species, for use in preclinical studies, and will also be validated for use in clinical studies. NextGen Sciences’ multiple reaction monitoring (MRM) protein assay platform is ideal for studies of this kind, which involve multiple isoforms and multiple species.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena